Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000363044 | SCV000415691 | uncertain significance | Familial hemophagocytic lymphohistiocytosis | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000529971 | SCV000648532 | likely benign | Familial hemophagocytic lymphohistiocytosis 5 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001753791 | SCV001985768 | uncertain significance | not provided | 2024-11-14 | criteria provided, single submitter | clinical testing | Reported as an apparently homozygous variant in an individual with hemophilia A, but no additional phenotypic information was provided on this individual beyond the bleeding phenotype (PMID: 34050687); Identified in the heterozygous state in patients in the published literature with suspected familial hemophagocytic lymphohistiocytosis or a suspected bleeding disorder, but no variant was identified on the other allele (PMID: 24916509, 32935436, 36706356); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32256442, 36706356, 32935436, 24916509, 34050687, 36588876) |
Genetic Services Laboratory, |
RCV001821007 | SCV002066027 | uncertain significance | not specified | 2019-08-15 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002263597 | SCV002542991 | uncertain significance | Autoinflammatory syndrome | 2017-03-09 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001821007 | SCV002570832 | uncertain significance | not specified | 2023-11-16 | criteria provided, single submitter | clinical testing | Variant summary: STXBP2 c.1586G>C (p.Arg529Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0014 in 247752 control chromosomes, predominantly at a frequency of 0.0024 within the Non-Finnish European subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in STXBP2 causing Familial Hemophagocytic Lymphohistiocytosis (0.0014 vs 0.0022), allowing no conclusion about variant significance. c.1586G>C has been reported in the literature in heterozygous individuals with clinically-suspected Familial Hemophagocytic Lymphohistiocytosis who were also heterozygous for a variant in PRF1 (e.g. Zhang_2014, Noori_2023). The variant was also found in a homozygous individual with haemophilia A without strong evidence for causality (Carrel_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Familial Hemophagocytic Lymphohistiocytosis. One publication reports experimental evidence evaluating an impact on protein function, suggesting normal cytotoxic activity of CD8+ T and NK cells in vitro, however, it does not allow convincing conclusions about the variant effect in disease (Noori_2023). The following publications have been ascertained in the context of this evaluation (PMID: 34050687, 36706356, 24916509). Eight submitters have cited clinical-significance assessments for this variant to ClinVar after 2014, classifying the variant as uncertain significance (n=7) or likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Population Bio, |
RCV001753791 | SCV002572504 | association | not provided | 2022-08-30 | criteria provided, single submitter | case-control | STXBP2 variant c.1586G>C (rs35490401) is associated with Progressive multifocal leukoencephalopathy (PML, ORPHA:217260). |
Center for Genomic Medicine, |
RCV001821007 | SCV002761038 | uncertain significance | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001753791 | SCV004224552 | uncertain significance | not provided | 2022-09-30 | criteria provided, single submitter | clinical testing | |
Birmingham Platelet Group; University of Birmingham | RCV001270501 | SCV001450800 | uncertain significance | Abnormal bleeding; Thrombocytopenia | 2020-05-01 | no assertion criteria provided | research | |
Prevention |
RCV003401347 | SCV004104363 | likely benign | STXBP2-related disorder | 2024-02-20 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |